QQQ2.88%

Trending

SPCX24.02%

home Symbol CTORnews

CTORCitius Oncology Inc.

$0.68

$0.0162

(2.44%)

Today

Closed $0.6802

$0.0002

(0.03%)

After Hours

Updated: 05:35 PM EDT

Mkt Cap$61.74M

Vol32,368.00

Fundamentals

Mkt Cap

$61.74M

52W High

$6.19

52W Low

$0.4912

PE Ratio

-1.42

Avg. Volume

89,947.87

EPS (Annual)

-$0.338

Info

News

all

press releases

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin...

PR Newswire

More News

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR...

PR Newswire

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides...

PR Newswire

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and...

PR Newswire

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR Commercialization

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR Commercialization Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR Commercialization PR Newswire CRANFORD, N.J., May 5, 2026 Avenue Capital Group to...

PR Newswire

Citius Oncology Ships First International Order of LYMPHIR to Europe

Citius Oncology Ships First International Order of LYMPHIR to Europe Citius Oncology Ships First International Order of LYMPHIR to Europe PR Newswire CRANFORD, N.J., April 29, 2026 Order fulfilment expands international patient access to LYMPHIR following initial U.S. launchDistribution by regional...

PR Newswire

Citius Oncology (NASDAQ:CTOR) Trading 9% Higher - What's Next?

Citius Oncology (NASDAQ:CTOR) Trading Up 9% - Time to Buy...

MarketBeat

Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development

Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting...

PR Newswire

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts PR Newswire CRANFORD...

PR Newswire

Citius Oncology (NASDAQ:CTOR) Trading Down 2.8% - Here's What Happened

Citius Oncology (NASDAQ:CTOR) Stock Price Down 2.8% - Time to Sell...

MarketBeat

...

Advertisement|Remove ads.